Articles from GordonMD Global Investments

Rapalogix Health, a biotechnology company advancing a science-first approach to cellular longevity and skin health, today announced the closing of a $20 million Series A financing co-led by GordonMD Global Investments® LP (“GordonMD”) — the Beverly Hills-based physician-led biopharma investment firm — and Woodline Partners. The round reflects GordonMD’s conviction that mechanism-driven platforms in dermatology represent a compelling and underserved frontier in biopharma. Proceeds will fund the national commercial expansion of Re-Q Health and IND-enabling development of RLX-202, the company’s prescription therapeutic lead candidate for aesthetic dermatology.

GordonMD Global Investments® today announced that it has participated in an oversubscribed $125 million Series D financing for Star Therapeutics, a clinical-stage biotechnology company discovering and developing novel antibodies for bleeding disorders and other diseases. GordonMD Global Investments® is among Star’s new investors, underscoring the firm’s commitment to advancing transformative therapies in hematology.

GordonMD® Global Investments today announced that portfolio company Radionetics Oncology, a leader in developing targeted radiopharmaceuticals for cancer treatment, has entered into a strategic agreement with Eli Lilly and Company, (NYSE: LLY).

Today Craig Gordon, MD, a licensed physician with over a decade of buy-side experience managing global biopharmaceutical portfolios, proudly announces the launch of GordonMD Global Investments. The firm is focused on investments in private and publicly traded global growth and innovative biopharma companies primarily located in the U.S., Japan, and Europe.